This article is more than 5 years old. Information may no longer be current.

Xeomin demonstrates efficacy in treatment of upper facial lines

Xeomin demonstrated significant efficacy in treating three areas of upper facial lines, according to recently published study results.

Researchers studied 156 healthy adults with moderate-to-severe glabellar frown lines, horizontal forehead lines and lateral periorbital lines.

In the randomized trial, 105 patients (mean age, 47.4 years; 89.5% women) were assigned to Xeomin (incobotulinumtoxinA; Merz Aesthetics) and 51 patients (mean age, 47.5 years; 80.4% women) were assigned to placebo. One injection of incobotulinumtoxinA or placebo was placed in the three treatment areas. The incobotulinumtoxinA dose was 54 U to 64 U. administered. Investigator-assessed Merz Aesthetics Scales (MAS) scores were measured for each area at maximum contraction at day 30, including separately, with a responder having a score of 0 (none) or 1 (mild) out of 5, and combined for upper facial lines and a sum score of ≤ 3.

“A significant (P ≤ .0001) effect of incobotulinumtoxinA versus placebo for [glabellar frown lines] (84.5% vs. 0.0%), [horizontal forehead lines] (70.9% vs. 2.1%), [lateral periorbital lines] (64.1% vs. 2.1%), and [upper facial lines] combination (55.3% vs. 0.0%) was demonstrated for investigator-assessed ‘none’ or ‘mild’ scores” at day 30 of maximum contraction, the researchers wrote.

There were reports of two cases of mild eyelid ptosis in the inbotulinumtoxinA-treated cohort.

“IncobotulinumtoxinA demonstrated significant efficacy in treating [glabellar frown lines], [horizontal forehead lines] and [lateral periorbital lines] separately and combined,” the researchers concluded. “The effects were maintained up to 120 days, and the treatment was well-tolerated.” – By Bruce Thiel

Disclosure: Kerscher reports receiving research support from and conducting clinical trials for Merz Pharmaceuticals GmbH, and acting as a speaker and/or investigator for Merz, Kythera, Q-Med/Galderma and Pierre Fabre. Please see the study for a full list of the other researchers’ relevant financial disclosures.